← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kosan Biosciences, Inc.
Hayward, CA
$9,742,084
Total funding
27
Grants
Funding mix
By agency
NIH$9,742,084 · 27
By mechanism
R44$5,211,831 · 7
R43$4,530,253 · 20
Investigators at Kosan Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Metabolic Engineering of Yeast for Polyketide Production$375,000
R44 · FY2001 · GM
New Ketolide Antibacterial Drugs$375,000
R44 · FY2003 · AI
Overproduction of polyketide antimicrobials$375,000
R44 · FY2004 · AI
New Ketolide Antibacterial Drugs$375,000
R44 · FY2005 · AI
Novel Geldanamycin Analogs as Anti-Tumor Agents$375,000
R44 · FY2005 · CA
Efficient synthesis of discodermolide$375,000
R44 · FY2005 · CA
Metabolic Engineering of Yeast for Polyketide Production$375,000
R44 · FY2002 · GM
Novel Geldanamycin Analogs as Anti-Tumor Agents$375,000
R44 · FY2004 · CA
New Ketolide Antibacterial Drugs$375,000
R44 · FY2004 · AI
Efficient synthesis of discodermolide$375,000
R44 · FY2004 · CA
Overproduction of polyketide antimicrobials$375,000
R44 · FY2003 · AI
HETEROLOGOUS PRODUCTION OF EPOTHILONE$338,713
R44 · FY2003 · CA
HETEROLOGOUS PRODUCTION OF EPOTHILONE$328,848
R44 · FY2002 · CA
HETEROLOGOUS PRODUCTION OF EPOTHILONE$319,270
R44 · FY2001 · CA
TACROLIMUS (FK506) ANALOGS WITH HIGHER BIOAVAILABILITY$300,458
R43 · FY2001 · AI
Leptomycin B Analogs$300,000
R43 · FY2005 · CA
Leptomycin B Analogs$300,000
R43 · FY2004 · CA
Anti-infectives with Multi-domain Ribosomal Binding$296,598
R43 · FY2001 · AI
Novel Macrolide Antibiotics$294,250
R43 · FY2003 · AI
Novel Macrolide Antibiotics$294,250
R43 · FY2002 · AI